Rachael Denae Barszczowski, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 217 S Logan Blvd, Burnham, PA 17009 Phone: 717-248-5431 Fax: 717-248-5038 |
Ms. Jaclyn Gleske, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
Jonathan White, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
Ms. Stefanie Dunk, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 570-242-0701 |
Abbey Solt, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
Mandy Lynne Corman, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
David C Hearn, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
Heather A Shevchik O'brien, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 224 N Logan Blvd, Burnham, PA 17009 Phone: 717-242-0196 Fax: 717-242-0701 |
News Archive
Candela Corporation, a Syneron company, announced today that the SFDA (State Food and Drug Administration) of China has approved the Alex TriVantage® multi-wavelength, Q-switched laser system and the GentleMax® multiple wavelength workstation for sale throughout the People's Republic of China, including Hong Kong.
Today, final details of the White House budget proposal for family planning and reproductive health were made public. The Obama administration is proposing $715.7 million for bilateral and multilateral international family planning and reproductive health (FP/RH) assistance - a $67 million or a 10 percent increase above FY 2010.
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
Researchers have successfully developed human eggs in a laboratory in a major scientific first.
› Verified 6 days ago